Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Plus Therapeutics ( (PSTV) ) just unveiled an update.
On June 3, 2025, Plus Therapeutics, Inc. received a letter from Nasdaq stating that the company had regained compliance with Rule 5250(c)(1) after filing its Quarterly Report for the period ended March 31, 2025. However, the company was notified of non-compliance with the Minimum Stockholders’ Equity Requirement, leading to a decision to delist its securities unless an appeal is made. Plus Therapeutics plans to request a hearing to appeal this decision, during which its stock will continue trading on the Nasdaq Capital Market.
The most recent analyst rating on (PSTV) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Underperform.
The overall stock score is heavily impacted by the company’s challenging financial position and poor valuation metrics. Technical indicators also point to weak momentum. While there are some positive developments from the earnings call and strategic initiatives, these are overshadowed by financial and compliance risks.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Average Trading Volume: 14,959,714
Technical Sentiment Signal: Sell
Current Market Cap: $11.54M
See more data about PSTV stock on TipRanks’ Stock Analysis page.